2021
Influenza Antiviral Treatment and Length of Stay
Campbell AP, Tokars JI, Reynolds S, Garg S, Kirley PD, Miller L, Yousey-Hindes K, Anderson EJ, Oni O, Monroe M, Kim S, Lynfield R, Smelser C, Muse AT, Felsen C, Billing LM, Thomas A, Mermel E, Lindegren ML, Schaffner W, Price A, Fry AM. Influenza Antiviral Treatment and Length of Stay. Pediatrics 2021, 148: e2021050417. PMID: 34470815, DOI: 10.1542/peds.2021-050417.Peer-Reviewed Original ResearchConceptsLaboratory-confirmed influenzaAntiviral treatmentMedical conditionsHospitalized patientsIllness onsetHigh-risk medical conditionsInfluenza Hospitalization Surveillance NetworkKaplan-Meier survival analysisEarly antiviral treatmentEmpiric antiviral treatmentInfluenza antiviral treatmentLength of stayHospital lengthICU cohortMedian LOSSymptom onsetShorter hospitalizationPrevention recommendationsTime-dependent variablesCox modelAntiviral agentsSurvival analysisCohortDisease controlInfluenza
2013
Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005–2012
Greenbaum A, Chaves S, Perez A, Aragon D, Bandyopadhyay A, Bennett N, Fowler B, Hancock E, Lynfield R, McDonald-Hamm C, Reingold A, Ryan P, Schaffner W, Sharangpani R, Spencer M, Thomas A, Yousey-Hindes K, Zansky S, Finelli L. Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005–2012. Infection 2013, 42: 165-170. PMID: 24243481, DOI: 10.1007/s15010-013-0534-8.Peer-Reviewed Original Research